Kiniksa Pharmaceuticals International Quarterly Balance Sheet
NASDAQ: KNSAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Kiniksa Pharmaceuticals International financial position
As of Mar 31, 2026, Kiniksa Pharmaceuticals International reported total assets of $825.3 million, up 37.7% from a year earlier against total liabilities of $219.6 million. Shareholders' equity stood at $605.7 million, or 73.4% of assets. The company held $190.0 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 3.79, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Kiniksa Pharmaceuticals International balance sheet (quarterly)
| Quarter (USD) | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 | Q2 20232023-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 189.95M | 165.60M | 174.86M | 192.04M | 157.13M | 183.58M | 97.38M | 99.27M | 141.08M | 107.95M | 117.83M | 112.57M |
| Short-Term Investments | 278.14M | 248.48M | 177.24M | 115.75M | 111.21M | 60.05M | 126.40M | 119.49M | 72.47M | 98.42M | 83.26M | 72.42M |
| Receivables | 23.22M | 15.59M | 51.74M | 31.91M | 40.06M | 41.72M | 24.89M | 20.45M | 15.99M | 21.27M | 3.04M | 24.65M |
| Inventory | 73.14M | 54.90M | 41.40M | 48.18M | 22.07M | 26.36M | 28.68M | 34.86M | 27.28M | 31.12M | 25.58M | 23.96M |
| Total Current Assets | 594.17M | 527.18M | 475.53M | 420.31M | 355.91M | 331.80M | 311.30M | 301.02M | 270.59M | 276.30M | 256.11M | 246.04M |
| Property, Plant & Equipment | 1.99M | 1.94M | 1.66M | 1.08M | 606.00K | 662.00K | 561.00K | 625.00K | 712.00K | 734.00K | 918.00K | 1.14M |
| Intangible Assets | 15.00M | 15.25M | 15.50M | 15.75M | 16.00M | 16.25M | 16.50M | 16.75M | 17.00M | 17.25M | 17.50M | 17.75M |
| Total Assets | 825.28M | 763.63M | 712.33M | 661.15M | 599.33M | 580.55M | 555.30M | 542.43M | 519.67M | 526.32M | 483.06M | 484.33M |
| Accounts Payable | 24.40M | 2.03M | 6.15M | 8.96M | 1.98M | 2.04M | 8.33M | 7.39M | 5.63M | 8.25M | 1.01M | 648.00K |
| Total Current Liabilities | 156.61M | 139.18M | 123.59M | 117.83M | 97.27M | 100.62M | 95.95M | 84.29M | 64.21M | 63.67M | 53.47M | 47.47M |
| Total Liabilities | 219.59M | 196.03M | 176.95M | 166.14M | 141.84M | 142.12M | 118.29M | 107.33M | 87.78M | 87.48M | 77.94M | 72.68M |
| Shareholders' Equity | 605.69M | 567.61M | 535.38M | 495.01M | 457.49M | 438.44M | 437.01M | 435.10M | 431.89M | 438.84M | 405.13M | 411.66M |
| Retained Earnings | -439.55M | -462.14M | -476.34M | -494.77M | -512.60M | -521.14M | -512.25M | -499.56M | -495.65M | -477.95M | -503.19M | -489.33M |
| Net Cash (Debt) | 468.09M | 414.07M | 352.10M | 307.78M | 268.34M | 243.63M | 223.78M | 218.76M | 213.55M | 206.37M | 201.08M | 184.99M |
This table shows 12 quarterly periods of Kiniksa Pharmaceuticals International's balance sheet, from Q1 2026 back to Q2 2023, across 14 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow KNSA's reporting calendar. What is a balance sheet?